Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EyeCell
- Development stage
- Unknown
- Lead developer
- Leonhardt Ventures
- Modality
- Device-based Delivery → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies, Hydrogel Systems → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Implant, Ophthalmic
01
Overview
EyeCell is a regenerative therapy platform developed by Leonhardt Ventures for the treatment of vision loss and various eye diseases, including wet and dry macular degeneration and diabetic retinopathy. The system integrates an implantable bioelectric micro-regeneration stimulator and a micro-pump to deliver a proprietary biological composition known as EC-15. This composition contains fifteen regenerative components, including stem cells, exosomes, growth factors, microRNAs, and a nutrient hydrogel. The platform utilizes bioelectric microcurrent stimulation to modulate the expression of stem cell homing factors and growth factors, specifically Stromal cell-derived factor 1 (SDF-1), Insulin-like growth factor 1 (IGF-1), and Platelet-derived growth factor (PDGF), to facilitate tissue repair, cellular proliferation, and differentiation within the eye.
- Brand names
- EyeCell
- Other names
- EyeCell regenerative therapy platform
Beyond the preview
Go deeper on EyeCell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EyeCell.